Getting technical: Lessons from the emotional perception Remittal

​
October 28, 2026

The UK Supreme Court's decision in Emotional Perception AI Ltd v Comptroller-General of Patents, Designs and Trade Marks [2026] UKSC 3 has changed the way in which excluded subject matter is approached in the UK. However, following the case's remittal to the UK Intellectual Property Office (UKIPO), the patent application at the centre of that decision has now been refused again.

The remittal decision provides an important indication of what the Supreme Court's new approach is likely to mean in practice. In particular, just because an invention involves technical means does not mean that all its features will contribute to inventive step. Consistent with established practice at the European Patent Office (EPO), the more important question is which features contribute to a technical solution to a technical problem.

A new approach to excluded matter

The application concerned an artificial neural network (ANN) used to provide semantically relevant file recommendations. Broadly, the ANN is trained so that similarity between files in terms of objectively measurable properties corresponds more closely to their similarity in terms of semantic descriptions. Once trained, the ANN can be used to identify semantically similar files based on their measurable properties.

The Supreme Court concluded that the Aerotel approach previously applied in the UK should no longer be followed. Instead, the Court adopted an approach based on the principles set out in the EPO’s Enlarged Board of Appeal decision G 1/19. This represents a significant departure from established UK practice that emerged after Aerotel. Although the Aerotel approach may have been intended to produce broadly consistent outcomes with the EPO approach, in practice the two did not always lead to the same result. The Supreme Court's decision brings the UK approach to assessing excluded subject matter much closer to that of the EPO.  

Under the new approach, the initial threshold for establishing that claimed subject matter is an "invention" is relatively low. G 1/19 adopts the "any hardware" approach, under which reference to a computer or other technical means can be sufficient to clear the Article 52 EPC exclusion.

The Supreme Court held that Emotional Perception's claims passed that threshold. Although it concluded that an ANN is a "program for a computer", the claimed subject matter was not a computer program "as such". The ANN had to be implemented on some form of computer hardware and the claims expressly referred to hardware including a database, communications network and user device. This was sufficient for the claimed subject matter to have technical character.

That, however, was only the first hurdle.

The Supreme Court identified a further "intermediate step", derived from G 1/19, between determining whether the claimed subject matter constitutes an invention and assessing inventive step. This considers which features contribute to the technical character of the invention as a whole. The UKIPO subsequently set out the resulting three-stage approach in its practice notice, published on 14 July 2026: first, determine whether the claimed subject matter is an invention (i.e. whether it passes the "any hardware" test); second, identify which features contribute to its technical character (this is the "intermediate step"); and third, assess inventive step based on the features making that contribution. As expressed in the practice notice, a feature makes such a contribution where it contributes to, or interacts with, the technical subject matter of the claim to provide a technical solution to a technical problem. Features which do not do so cannot support inventive step.

Importantly, this is not simply a question of dividing a claim into features which appear technical and features which appear non-technical. The Supreme Court explained that even a feature which is technical in isolation may fail to contribute if it has no technical function in the context of the claimed invention. Conversely, a feature which is non-technical in isolation may nevertheless contribute where it interacts with the technical subject matter of the claim in solving a technical problem.

The Supreme Court did not itself decide how that analysis should apply to Emotional Perception's claims. It instead remitted the application to the UKIPO, observing that it had not received sufficient argument on how the new intermediate step should be applied to the particular invention.

Applying the new approach

The remittal was not the UKIPO’s first opportunity to apply the new approach. An earlier Hearing Officer decision BL O/0673/26 in relation to an application by FLIR Belgium BV, issued in July 2026, had already considered which claimed features contributed to the technical character of an invention when assessing inventive step. The Emotional Perception remittal is nonetheless particularly illustrative because it shows how the new approach was applied to the application at the centre of the Supreme Court proceedings themselves.  

On 1 October 2026, the UKIPO issued its decision following remittal in BL O/0894/26. The application was refused again, but on different grounds from the initial refusal. Following the Supreme Court judgment, the application was examined under the new approach and the outstanding questions were considered by the Hearing Officer.

The Hearing Officer focused on claim 4, a computer-implemented method of providing semantically relevant file recommendations. In broad terms, the claimed method trained the ANN so that distances derived from measurable properties of files converged towards corresponding semantic distances. The trained ANN was then used to identify and output files considered semantically similar to a target file.

Applying the new intermediate step, the critical issue was which features contributed to the technical character of the invention and could therefore be taken into account when assessing inventive step. The Hearing Officer concluded that outputting a "semantically better" file was not a technical result. Consequently, the ANN's learning objectives and its training to close the "semantic gap" could not contribute to the technical character of the claim and could not therefore support inventive step.

Once those features were disregarded for that purpose, what remained (specifically, “Computer hardware running a program that selects and outputs a file”) was considered obvious over the common general knowledge. The application was therefore refused for lack of inventive step.

What are the key questions?  

This new approach puts considerable emphasis on a question already central to the patentability of computer-implemented inventions before the EPO: is there a technical solution to a technical problem, and which features provide it?  

This is a question I regularly ask inventors working in areas close to the boundary of patentability. It can provide a useful early indication of whether patent protection is likely to be appropriate, particularly for inventions where the innovation appears to lie in subject matter that the EPO may consider non-technical. Common examples include classifying documents solely according to their textual content, automating a purely business or administrative process, or presenting information to a user based only on its cognitive content.

Perhaps more importantly, this question encourages consideration of where the technical innovation actually lies. For example, despite a product’s apparently non-technical purpose, is there nonetheless a non-obvious technical solution to a technical problem in its implementation? If so, patent protection may be more likely to be available.

What’s really changed?  

The impact of Emotional Perception is more nuanced than simply expanding the circumstances in which software and AI inventions can be patented in the UK. Clearing the relatively low initial “any hardware” hurdle still leaves the often more difficult question of which features of the invention actually contribute to its technical character and can therefore support inventive step.

Precisely how the new three-stage approach will be applied in practice is likely to develop as the UKIPO gains experience of it and further cases are decided, including through any appeal of the present decision. The earlier FLIR decision already illustrates the importance, and potentially fact-sensitive nature, of determining which features contribute to the technical character of an invention. It may therefore take some time for outcomes to become more predictable.  

For applicants considering protection for AI and other computer-implemented inventions in the UK, the underlying question is as important as ever:

Which features contribute to a technical solution to a technical problem?  

The renewed refusal of Emotional Perception's application is a timely reminder of the importance of asking this question from the very start.

References

Emotional Perception AI Limited v Comptroller General of Patents, Designs and Trade Marks [2026] UKSC 3, UK Supreme Court, judgment of 11 February 2026. Full judgment (PDF)  

Search and Examination of UK Patent Applications under the Patents Act 1977 (as amended), UKIPO practice notice, published 14 July 2026. UKIPO guidance on GOV.UK  

Emotional Perception AI Ltd, BL O/0894/26, UK Intellectual Property Office, decision of 1 October 2026. Full decision (PDF)  

FLIR Belgium BV, BL O/0673/26, UK Intellectual Property Office, decision of 29 July 2026. Full decision (PDF)
‍


Developing an AI or software innovation? Understanding what makes your invention technically distinctive can be critical to securing patent protection.

Speak to author Felix Hall or contact us about protecting your innovation.

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Patents or Trade Secrets? When to Patent in Deep Tech Innovation
11 May 2026
Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.
#
Patenting
​
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​